Related Experiment Video
Updated: Aug 3, 2025
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Mechanical thrombectomy of distal cerebral vessel occlusions of the anterior circulation
Dominik Sepp1, Moritz Roman Hernandez Petzsche2, Teresa Zarth2
1Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, München, Germany. dominik.sepp@tum.de.
Abstract:
Mechanical thrombectomy (MT) is frequently performed for distal medium vessel occlusions (DMVO) of the anterior circulation in acute stroke patients. However, evidence for its clinical benefit remains scarce. In this study, we aim to investigate clinical course and safety outcomes of MT in comparison to standard medical therapy (SMT) in DMVO. This single-center retrospective observational study included 138 consecutive patients treated for DMVO of the anterior circulation between 2015 and 2021. To reduce the risk of selection bias, propensity score matching (PSM) of patients with MT versus SMT was performed for the covariates NIHSS and mRS at admission. Out of all 138 patients, 48 (34.8%) received MT and 90 (65.2%) received SMT only. Overall, patients treated with MT showed significantly higher NIHSS and mRS scores at admission. Post 1:1 PSM, there was a trend toward a better NIHSS improvement in patients with MT (median 4 vs. 1, P = 0.1). No significant differences were observed in the occurrence of symptomatic intracranial hemorrhage or mortality between the groups before and after PSM. A subgroup analysis showed significantly higher NIHSS improvement (median 5 versus 1, P = 0.01) for patients with successful MT (≥ mTICI 2b). Mechanical thrombectomy for distal medium vessel occlusions (DMVO) in the anterior circulation appeared safe and feasible. Successful recanalization was associated with clinical improvement. Larger, multi-center, randomized-controlled trials are required to corroborate these findings.
Insights
Mechanical thrombectomy (MT) for distal medium vessel occlusions (DMVO) in acute stroke is safe and feasible. Successful MT showed improved outcomes, but larger trials are needed to confirm benefits over standard medical therapy (SMT).
Area of Science:
- Neurology
- Interventional Neuroradiology
- Stroke Medicine
Background:
- Mechanical thrombectomy (MT) is increasingly used for acute stroke due to distal medium vessel occlusions (DMVO) in the anterior circulation.
- However, robust clinical evidence supporting its benefit over standard medical therapy (SMT) for DMVO is limited.
- This study evaluates the clinical course and safety of MT versus SMT in DMVO patients.
Purpose of the Study:
- To compare the effectiveness and safety of mechanical thrombectomy (MT) against standard medical therapy (SMT) for treating distal medium vessel occlusions (DMVO) in acute stroke.
- To assess clinical outcomes, including neurological improvement and safety events, in patients with DMVO.
- To investigate the impact of successful recanalization on patient outcomes.
Main Methods:
- A single-center retrospective observational study of 138 patients with DMVO treated between 2015 and 2021.
- Propensity score matching (PSM) was used to minimize selection bias between MT and SMT groups based on NIHSS and mRS scores.
- Outcomes analyzed included neurological improvement (NIHSS), functional status (mRS), symptomatic intracranial hemorrhage, and mortality.
Main Results:
- Of 138 patients, 48 received MT and 90 received SMT. MT patients had higher admission NIHSS and mRS scores.
- Post-PSM, a trend towards better NIHSS improvement was observed in the MT group (median 4 vs. 1, P=0.1).
- Successful MT (≥mTICI 2b) was significantly associated with greater NIHSS improvement (median 5 vs. 1, P=0.01). No significant differences in hemorrhage or mortality were found between groups.
Conclusions:
- Mechanical thrombectomy for DMVO in the anterior circulation appears safe and feasible.
- Successful recanalization during MT correlates with improved clinical outcomes in stroke patients.
- Further large-scale, multi-center randomized controlled trials are necessary to definitively establish the clinical benefit of MT for DMVO.
